CTIS2024-511430-12-00招募中1 期
ProSperA_CC-1
niversitaetsklinikum Tuebingen AöR0 个研究点目标入组 56 人开始时间: 2024年2月12日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men with Biochemical Recurrence after Definitive Local Therapy for Prostate CancerProstate CancerCTIS2023-504066-39-00Vaccitech PLC117
进行中（未招募）
1 期
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) - targeting, Bifunctional Antibody-fusion molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-Rich (START-001)nresectable, Locally Advanced, or Metastatic Solid TumorsCTIS2023-505334-10-00Marengo Therapeutics Inc.271
进行中（未招募）
1 期
Phase 1/2 study testing for the first time in humans a novel drug, STAR0602, to selectively stimulate T cells for the treatment of subjects with advanced solid tumors that cannot be removed with surgery or has spread locally or to other parts of the body.CTIS2023-505334-10-01Marengo Therapeutics Inc.271
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Pharmacokinetics of Single Ascending and Multiple Ascending Doses of Prosetin in Healthy Volunteers and Participants with Amyotrophic Lateral Sclerosis (ALS) with an Optional Open-Label Extended Treatment Period for ALS Participants who Complete 14 Days of Blinded TreatmentCTIS2023-507363-20-00Projenx Inc.24
进行中（未招募）
1 期
A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on how long the drug can stay in the body and if it can control the disease of people diagnosed with extensive small cell lung cancer and have not had any previous treatment for the disease. CC-90011, single agent, will be also given in consolidation after completion of the 4 to 6 cycles of chemotherapyextensive stage small cell lung cancerMedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10041067Term: Small cell lung cancer Class: 100000004864CTIS2023-509800-14-00Celgene Corp.66